Iomeprol
As of the edition of 20 October 2026, Iomeprol is a small molecule: marketed, first approved in 1996 (ES); US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Iomervu
- First approved
- 1 February 1996 (ES)
- Approvals on record
- 29 in 4 regions
- Holder of the most recent approval
- Bracco Diagnostics; 4 holders in all
- Registered trials
- 2, 0 stopped early
US protection
US protection ends in 2029.
The last listed US exclusivity ends in 2029. The application that gives this date is held by Bracco Diagnostics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product26 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 26 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bracco Diagnostics | Applicant | 2024 to now |